Validation of plasma metabolites associated with breast cancer risk among Mexican Americans. (December 2020)

• Record Type: Journal Article
• Authors: Zhao, Hua; Shen, Jie; Ye, Yuanqing; Wu, Xifeng; Esteva, Francisco J.; Tripathy, Debasish; Chow, Wong-Ho
• Is Part Of: Cancer epidemiology. Volume 69(2020:Dec.)
• Publication Date: 2020-12
• Subjects: Metabolomics -- Breast cancer -- Mexican americans; Cancer -- Epidemiology -- Periodicals; Cancer -- Prevention -- Periodicals; Cancer -- Diagnosis -- Periodicals; Carcinogenesis -- Periodicals; 616.994005
• DOI: 10.1016/j.canep.2020.101826
• Languages: English
• ISSNs: 1877-7821

Abstract

Highlights: We have validated four plasma metabolites associated with breast cancer risk in Mexican Americans. The validated metabolites were 3-hydroxyoctanoate, 3-hydroxybutyrate (BHBA), linoleate, and bilirubin. We have constructed a metabolic risk score that was associated with breast cancer risk. Abstract: In our previous breast cancer case control study in Hispanics, we found 14 metabolites whose levels differed between cases and controls. To validate the results, we carried out a nested case control study of 100 incident breast cancer and 100 matched healthy women identified from the Mano-A-Mano Mexican American Cohort study. With the adjustment of parity, education, birth place, language acculturation, BMI category, smoking, drinking, physical activity, and sitting time, 4 metabolites were associated with breast cancer risk: 3-hydroxyoctanoate (Odds ratio (OR) = 1.51, 95% confidence interval (CI): 1.10, 3.47), 3-hydroxybutyrate (BHBA) (OR = 1.42, 95%CI: 1.01, 3.72), linoleate (18:2n6) (OR = 1.39, 95% CI: 1.07, 4.04), and bilirubin (OR = 0.54, 95%CI: 0.42, 0.95). Then, we used 3 non-redundant metabolites, namely 3-hydroxyoctanoate, linoleate (18:2n6), and bilirubin, to generate a metabolic risk score. Increased metabolites risk score was associated with a 1.67-fold increased risk of breast cancer (OR = 1.67, 95%CI: 1.32, 3.94). And the significant association was more evident among those who were diagnosed with cancer earlier during the follow-up (≤ 5 years) than their counterparts. In conclusion, we identified four significant metabolites which may help elucidate metabolic pathways that contribute to breast carcinogenesis. Our findings warrant further replication efforts.